Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pazopanib Hydrochloride in Rhabdomyosarcoma: NCT06816771 Clinical Landscape Report 2026
15 October 2026
NCT06816771 clinical landscape for Rhabdomyosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Finerenone in Renal Cell Carcinoma: NCT06818305 Clinical Landscape Report 2026
15 October 2026
NCT06818305 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IB-T101 in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT06819293 Clinical Landscape Report 2026
15 October 2026
NCT06819293 clinical landscape for Locally Advanced Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Etoposide in Small Cell Carcinoma: NCT06820957 Clinical Landscape Report 2026
15 October 2026
NCT06820957 clinical landscape for Small Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Adebrelimab in Triple Negative Breast Cancer: NCT06819319 Clinical Landscape Report 2026
15 October 2026
NCT06819319 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
KJ-C2219 in Scleroderma, Diffuse: NCT06822881 Clinical Landscape Report 2026
15 October 2026
NCT06822881 clinical landscape for Scleroderma, Diffuse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
XS-04 in Acute Myeloid Leukemia: NCT06820268 Clinical Landscape Report 2026
15 October 2026
NCT06820268 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Ewing Sarcoma: NCT06827717 Clinical Landscape Report 2026
15 October 2026
NCT06827717 clinical landscape for Ewing Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Quisinostat Hydrochloride in Glioblastoma: NCT06824662 Clinical Landscape Report 2026
15 October 2026
NCT06824662 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
QH-103 in Granulomatosis With Polyangiitis: NCT06828042 Clinical Landscape Report 2026
15 October 2026
NCT06828042 clinical landscape for Granulomatosis With Polyangiitis: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Invikafusp alfa in Advanced Malignant Solid Neoplasm: NCT06827613 Clinical Landscape Report 2026
15 October 2026
NCT06827613 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy(AHS Cancer Control Alberta) in Alveolar Soft Part Sarcoma: NCT06827886 Clinical Landscape Report 2026
15 October 2026
NCT06827886 clinical landscape for Alveolar Soft Part Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.